NeoGenomics, Inc. (NASDAQ:NEO) – Gabelli dropped their FY2017 EPS estimates for NeoGenomics in a report released on Thursday. Gabelli analyst S. Wojda now anticipates that the medical research company will post earnings per share of $0.01 for the year, down from their prior forecast of $0.06. Gabelli currently has a “Buy” rating and a $9.00 price target on the stock. Gabelli also issued estimates for NeoGenomics’ FY2018 earnings at $0.16 EPS.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Janney Montgomery Scott restated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. ValuEngine upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Finally, BTIG Research cut shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. NeoGenomics currently has an average rating of “Buy” and an average target price of $10.33.

Shares of NeoGenomics (NEO) opened at $9.16 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. NeoGenomics has a one year low of $7.12 and a one year high of $11.63. The firm has a market cap of $734.14, a PE ratio of 182.60, a P/E/G ratio of 11.41 and a beta of 0.85.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The business had revenue of $63.05 million during the quarter, compared to analysts’ expectations of $63.11 million. During the same quarter last year, the company earned $0.04 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. TIAA CREF Investment Management LLC raised its stake in shares of NeoGenomics by 0.4% in the second quarter. TIAA CREF Investment Management LLC now owns 149,220 shares of the medical research company’s stock valued at $1,337,000 after acquiring an additional 581 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of NeoGenomics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 199,654 shares of the medical research company’s stock valued at $1,789,000 after acquiring an additional 1,235 shares during the last quarter. Rhumbline Advisers raised its stake in shares of NeoGenomics by 3.6% in the second quarter. Rhumbline Advisers now owns 61,500 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 2,135 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of NeoGenomics by 3.1% in the first quarter. Teachers Advisors LLC now owns 96,168 shares of the medical research company’s stock valued at $759,000 after acquiring an additional 2,854 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of NeoGenomics by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 46,245 shares of the medical research company’s stock valued at $414,000 after acquiring an additional 3,058 shares during the last quarter. Hedge funds and other institutional investors own 83.73% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Research Analysts Issue Forecasts for NeoGenomics, Inc.’s FY2017 Earnings (NEO)” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://theolympiareport.com/2017/12/05/research-analysts-issue-forecasts-for-neogenomics-inc-s-fy2017-earnings-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.